


## PHARMACEUTICAL 2021

## Dyne Therapeutics Inc. Rank 69 of 409





## PHARMACEUTICAL 2021



## Dyne Therapeutics Inc. Rank 69 of 409

The relative strengths and weaknesses of Dyne Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dyne Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 261% points. The greatest weakness of Dyne Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 429% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	349,087
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,967
Liabilities, Non-Current	0
Other Assets	2,301
Other Compr. Net Income	-27
Other Expenses	0
Other Liabilities	0
Other Net Income	-790
Property and Equipment	1,946
Research and Development	45,200
Revenues	0
Selling, General and Administrative Expense	13,447

Output Variable	Value in 1000 USD
Assets	353,334
Liabilities	10,967
Expenses	58,647
Stockholders Equity	342,367
Net Income	-59,437
Comprehensive Net Income	-59,450
Economic Capital Ratio	74%